USD 1.57 billion
Report ID:
SQSG35I2023 |
Region:
Global |
Published Date: April, 2024
Pages:
165
|Tables:
90
|Figures:
76
Neuroendocrine Tumors Treatment Market size was valued at USD 1.7 Billion in 2023 and is poised to grow from USD 1.84 Billion in 2024 to USD 3.55 Billion by 2032, growing at a CAGR of 8% during the forecast period (2025-2032).
The prevalence of cancers is rising significantly on a global scale. Rare tumors called neuroendocrine tumors (NET) develop from the cells of the neurological system and endocrine/hormonal system. Known as carcinoid tumors, neuroendocrine tumors typically develop in the gastrointestinal tract but can also develop in the appendix, rectum, pancreas, and lungs. Neuroendocrine tumors can either have a benign or cancerous nature.
Constipation, diarrhea, stomachaches, chronic coughing, low blood sugar, changes in blood pressure, heart problems, and other symptoms are all signs of neuroendocrine tumors. Rising neuroendocrine tumor prevalence, increased R&D spending, new product introductions, and early detection thanks to improved diagnostic methods are expected to accelerate the market for treatments for neuroendocrine tumors worldwide over the forecast period.
US Neuroendocrine Tumors Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 1.57 billion
Largest Segment
Hospitals
Fastest Growth
Hospitals
Growth Rate
8% CAGR
To get more reports on the above market click here to Buy The Report
The Global Neuroendocrine Tumors Treatment Market is segmented based on treatment type, end user, indication, and region. Based on treatment type, it is categorized into Somatostatin Analogy, Targeted Therapy, and Chemotherapy. Based on the end user, it is categorized into hospitals and clinics. Based on indication, it is categorized into Gastric Neuroendocrine Tumors, Lung Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, and Appendicular Neuroendocrine Tumors. Based on region, it is categorized into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Neuroendocrine Tumors Treatment Market Analysis by Treatment Type
On the basis of treatment type, Somatostatin analogues are anticipated to dominate the market by Treatment Type in the forecasted period , accounting for the largest percentage of the overall market revenue share. Innovative non-cytotoxic and novel cytotoxic drugs techniques are being developed for the treatment of cancer due to the limited efficacy and severe toxicity of conventional chemotherapy. Somatostatin analogues are among the many hormonal agents, and they are widely employed because they have promising results. It is widely used because of its innovative qualities, which helps the market flourish.
Neuroendocrine Tumors Treatment Market Analysis by Indication
On the basis of indications, stomach neuroendocrine tumors are expected to account for the largest percentage in the forecast period. Due to an unhealthy lifestyle and poor eating practices, patients may develop gastrointestinal carcinoid tumors, a cancer that develops in the lining of the GI tract. The rising popularity and demand, due to the increasing number of patients with stomach neuroendocrine tumors, has aided this segment in gaining the largest market share.
Neuroendocrine Tumors Treatment Market Analysis by End user
On the basis of end-user, hospitals are predicted to hold the largest proportion in the forecasted period. The rising market share of hospitals is caused by the rising demand for cancer detection and treatment as well as the large number of walk-in patients for a variety of ailments. They are also preferred by the patients due to factors such as easy access to a wide range of chronic illness treatments available in the hospitals and the emergency care facilities that are provided.
To get detailed analysis on other segments, Request For Free Sample Report
Based on region, North America is predicted to experience considerable growth in the neuroendocrine tumor treatment market, due to the increasing acceptance of novel neuroendocrine tumor treatments in the region. For instance, Ipsen's Somatuline Depot (lanreotide) Injection 120 mg was approved by the U.S. Food and Drug Administration (FDA) and it is intended for the treatment of adults with advanced or metastatic, moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Because more medications are being approved by the European Commission (EC) for sale in European nations, the market for treating neuroendocrine tumors in Europe is anticipated to develop significantly over the course of the forecast period. For instance, the European Commission (EC) approved Lutathera (lutetium (177Lu) oxodotreotide) in September 2017 for the treatment of patients with progressive, well-differentiated, unresectable or metastatic gastroenteropancreatic neuroendocrine tumors that express the somatostatin receptor (GEP-NETs). With the exception of Iceland, Norway, and Liechtenstein, all 28 members of the European Union are now able to market Lutathera thanks to the authorisation.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Neuroendocrine Tumors Treatment Market Drivers
Neuroendocrine Tumors Treatment Market Restraints
Request Free Customization of this report to help us to meet your business objectives.
Due to the presence of a sizable number of participants, the market is quite competitive. To increase their consumer base, the majority of businesses are engaging in strategic alliances like mergers and acquisitions. To draw in more customers, players are diversifying their product offerings.
Neuroendocrine Tumors Treatment Market Top Players Company Profiles
Neuroendocrine Tumors Treatment Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyzes the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to the analysis, the global neuroendocrine tumor treatment market is currently led by the countries in the North American region with Somatostatin analogues anticipated to dominate the market share, due to the more effective results associated with it, over the forecast period.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 1.57 billion |
Market size value in 2031 | USD 3.29 billion |
Growth Rate | 8% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
Historical Year | 2019 |
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Neuroendocrine Tumors Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Neuroendocrine Tumors Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Neuroendocrine Tumors Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Neuroendocrine Tumors Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Neuroendocrine Tumors Treatment Market size was valued at USD 1.57 billion in 2019 and is poised to grow from USD 1.7 billion in 2023 to USD 3.29 billion by 2031, growing at a CAGR of 8% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQSG35I2023
sales@skyquestt.com
USA +1 351-333-4748